Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
NCT07917364, Recruiting, University of Applied Sciences in Nowy Targ
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Asprosin and miRNA Expression in Young Women With Metabolic Syndrome | ClinicalTrials.gov |
| NCT number | NCT07917364 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 110 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Applied Sciences in Nowy Targ | ClinicalTrials.gov |
| Conditions | Metabolic Syndrome, Insulin Resistance, Obesity, Abdominal, Dyslipidemias | ClinicalTrials.gov |
| Interventions | Biomarker panel (asprosin, microRNA, BDNF, cortisol), Clinical and questionnaire assessment | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Serum asprosin concentration | At the single study visit (Day 1) | Fasting serum asprosin concentration measured by enzyme-linked immunosorbent assay, compared between women with metabolic syndrome and healthy controls. Reported in ng/mL. | ClinicalTrials.gov |
| Primary | Expression of selected circulating microRNAs | At the single study visit (Day 1) | Relative expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) quantified in plasma by reverse-transcription quantitative PCR. Expression is normalized using ath-miR159a as an exogenous spike-in control and hsa-miR-186-5p as a reference. All six analytes are measured by the same method and reported in the same unit of measure, relative fold change, with results reported separately for each microRNA. | ClinicalTrials.gov |
| Secondary | Prevalence of individual metabolic syndrome components | At the single study visit (Day 1) | Proportion of participants in each group meeting each of the five NCEP ATP III components: elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose, and abdominal obesity. Reported as percentage of participants. | ClinicalTrials.gov |
| Secondary | Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | At the single study visit (Day 1) | HOMA-IR calculated from fasting glucose and fasting insulin as (fasting insulin in microU/mL x fasting glucose in mg/dL) / 405, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. | ClinicalTrials.gov |
| Secondary | Castelli Risk Index I | At the single study visit (Day 1) | Ratio of total cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk. | ClinicalTrials.gov |
| Secondary | Body fat percentage | At the single study visit (Day 1) | Body fat percentage (PBF) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported as a percentage of total body mass. | ClinicalTrials.gov |
| Secondary | Serum brain-derived neurotrophic factor (BDNF) concentration | At the single study visit (Day 1) | Fasting serum BDNF concentration measured by enzyme-linked immunosorbent assay, compared between groups and correlated with metabolic syndrome components. Reported in ng/mL. | ClinicalTrials.gov |
| Secondary | Serum cortisol concentration | At the single study visit (Day 1) | Fasting serum cortisol concentration measured by immunoassay, compared between groups and correlated with perceived stress and sleep quality scores. Reported in micrograms/dL. | ClinicalTrials.gov |
| Secondary | Quantitative Insulin Sensitivity Check Index (QUICKI) | At the single study visit (Day 1) | QUICKI calculated from fasting glucose and fasting insulin as 1 / (log fasting insulin in microU/mL + log fasting glucose in mg/dL), compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin sensitivity. | ClinicalTrials.gov |
| Secondary | Metabolic Score for Insulin Resistance (METS-IR) | At the single study visit (Day 1) | METS-IR calculated from fasting glucose, fasting triglycerides, body mass index and HDL cholesterol, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. | ClinicalTrials.gov |
| Secondary | Triglyceride-Glucose Index (TyG) | At the single study visit (Day 1) | TyG index calculated as the natural logarithm of (fasting triglycerides in mg/dL x fasting glucose in mg/dL) / 2, compared between the metabolic syndrome group and the control group. Reported as an index score (unitless). Higher values indicate greater insulin resistance. | ClinicalTrials.gov |
| Secondary | Castelli Risk Index II | At the single study visit (Day 1) | Ratio of LDL cholesterol to HDL cholesterol, calculated from the fasting lipid profile and compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). Higher values indicate greater atherogenic risk. | ClinicalTrials.gov |
| Secondary | Atherogenic Index of Plasma (AIP) | At the single study visit (Day 1) | Base-10 logarithm of the ratio of fasting triglycerides to HDL cholesterol, both expressed in mmol/L, compared between the metabolic syndrome group and the control group. Reported as a log-transformed ratio (unitless). Higher values indicate greater atherogenic risk. | ClinicalTrials.gov |
| Secondary | Fat-free mass | At the single study visit (Day 1) | Fat-free mass (FFM) measured by bioelectrical impedance analysis, compared between the metabolic syndrome group and the control group. Reported in kilograms. | ClinicalTrials.gov |
| Secondary | Body Mass Index (BMI) | At the single study visit (Day 1) | Body mass index calculated as body mass in kilograms divided by the square of body height in metres, compared between the metabolic syndrome group and the control group. Reported in kg/m\^2. | ClinicalTrials.gov |
| Secondary | Waist-to-Hip Ratio (WHR) | At the single study visit (Day 1) | Ratio of waist circumference to hip circumference, both measured in centimetres with an anthropometric tape, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). | ClinicalTrials.gov |
| Secondary | Waist-to-Height Ratio (WHtR) | At the single study visit (Day 1) | Ratio of waist circumference to body height, both measured in centimetres, compared between the metabolic syndrome group and the control group. Reported as a ratio (unitless). | ClinicalTrials.gov |
| Secondary | A Body Shape Index (ABSI) | At the single study visit (Day 1) | ABSI calculated from waist circumference, body mass index and body height according to Krakauer and Krakauer, compared between the metabolic syndrome group and the control group. Reported as an index score. Higher values indicate greater central adiposity relative to body size. | ClinicalTrials.gov |
| Secondary | Hip Index (HI) | At the single study visit (Day 1) | Hip Index calculated from hip circumference adjusted for body height and body mass, compared between the metabolic syndrome group and the control group. Reported as an index score. | ClinicalTrials.gov |
| Secondary | Body Adiposity Index (BAI) | At the single study visit (Day 1) | BAI calculated from hip circumference and body height, compared between the metabolic syndrome group and the control group. Reported as estimated body fat expressed as a percentage of total body mass. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 29
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 22815707 | BACKGROUND | PubMed |
| 23032062 | BACKGROUND | PubMed |
| 25244618 | BACKGROUND | PubMed |
| 25842981 | BACKGROUND | PubMed |
| 26180810 | BACKGROUND | PubMed |
| 26311337 | BACKGROUND | PubMed |
| 27087445 | BACKGROUND | PubMed |
| 27785570 | BACKGROUND | PubMed |
| 27922090 | BACKGROUND | PubMed |
| 27923453 | BACKGROUND | PubMed |
| 29480368 | BACKGROUND | PubMed |
| 29535168 | BACKGROUND | PubMed |
| 30471116 | BACKGROUND | PubMed |
| 30618797 | BACKGROUND | PubMed |
| 30853600 | BACKGROUND | PubMed |
| 31230984 | BACKGROUND | PubMed |
| 31435783 | BACKGROUND | PubMed |
| 31510055 | BACKGROUND | PubMed |
| 32153505 | BACKGROUND | PubMed |
| 32872598 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)